Physician profile
David M Ash
NPI 1295110542
$12,497.65
in general payments reported to CMS, 2019-2025
34 companies · $2,755 in 2025
The $2,755 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $627 · 2021: $2,391 · 2022: $1,689 · 2023: $2,171 · 2024: $2,864 · 2025: $2,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,790.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,612.90 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,501.27 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $1,234.39 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $864.23 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $726.39 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $514.78 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $510.89 | 2021-2025 | Rexulti |
| Tris Pharma INC | $469.09 | 2021-2025 | Dyanavel Xr |
| Corium, LLC | $424.14 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $421.54 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $370.17 | 2020-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $363.56 | 2021-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $324.13 | 2021-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $306.80 | 2023-2024 | Jornay Pm |
| Alkermes, INC. | $218.82 | 2020-2025 | Aristada, Lybalvi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $214.10 | 2020-2023 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $204.04 | 2023-2025 | Aplenzin |
| Noven Therapeutics, LLC | $175.71 | 2022-2025 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $151.48 | 2022-2025 | Auvelity, Sunosi |
| Eisai INC. | $147.50 | 2020 | |
| Allergan, INC. | $112.57 | 2020 | |
| Idorsia Pharmaceuticals US INC | $91.53 | 2023-2024 | Quviviq |
| Almatica Pharma LLC | $77.96 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| E.R. Squibb & Sons, L.L.C. | $72.66 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $72.58 | 2022-2023 | Belsomra |
| Brainsway USA INC | $71.36 | 2025 | Deep Tms System |
| Collegium Pharmaceutical, INC. | $67.95 | 2025 | Jornay Pm |
| Indivior INC. | $37.46 | 2023 | Perseris |
| Adlon Therapeutics L.P. | $33.76 | 2021 | |
| Jazz Pharmaceuticals INC. | $29.78 | 2021 | |
| Tonix Medicines, INC. | $21.72 | 2025 | Tonmya |
| Biogen, INC. | $19.55 | 2024 | |
| Avanir Pharmaceuticals, INC. | $17.22 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.62 | 2024 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.